

Dear

FREEDOM OF INFORMATION – CANCER TREATMENT

I write in response to your request for information in relation to cancer treatment in NHS Lothian.

Question:

1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Answer:

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	50
1.2 Alpelisib (Piqray)	Nil
1.3 Fulvestrant (fulvestrant or Faslodex)	48
1.4 Palbociclib (Ibrance)	71
1.5 Ribociclib (Kisqali)	53

Question:

2. How many patients received abemaciclib (Verzenios) for **early breast cancer** in the 3 months between the start of October 2023 and end of December 2023?

Answer:

Number patients treated
26

Question:

3. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of October 2023 and end of December 2023?

Answer:

Treatment intent	Number patients treated
3.1 Curative	34
3.2 Palliative	16
3.3 Not known / stated	Nil

Question:

4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2023 and end of December 2023?

Answer:

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	6
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	13
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	9

PROSTATE CANCER

Question:

5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Answer:

I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Name of medicine	Number patients treated
5.1 Abiraterone (Zytiga or generic abiraterone)	281
5.2 Apalutamide (Erleada)	≤5
5.3 Cabazitaxel (Jevtana or generic cabazitaxel)	7

5.4 Darolutamide (Nubeqa)	12
5.5 Enzalutamide (Xtandi)	140

Question:

6. How many patients were treated with docetaxel specifically for **prostate cancer** (ICD-10 code = C61) in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine	Number patients treated
Docetaxel	11

Question:

7. How many patients were treated with the following medicine combinations in the 3 months between the start of October 2023 and end of December 2023?

Answer:

I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Name of medicine	Number patients treated
7.1 Abiraterone (Zytiga or abiraterone) + Androgen Deprivation Therapy	281
7.2 Apalutamide (Erleada) + Androgen Deprivation Therapy	≤5
7.3 Darolutamide (Nubeqa) + Docetaxel + ADT	Nil
7.4 Enzalutamide (Zytiga) + Androgen Deprivation Therapy	140

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuporelin, triptorelin, degarelix, flutamide

OVARIAN and ENDOMETRIAL CANCERS

Question:

8. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Answer:

I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Name of medicine	Number patients treated
8.1 Dostarlimab (Jemperli)	≤5
8.2 Niraparib (Zejula)	31
8.3 Rucaparib (Rubraca)	Nil

Question:

9. How many patients were treated for **ovarian, fallopian tube or primary peritoneal cancers**, with the following medicines as monotherapy or in combination, in the 3 months between the start of October 2023 and end of December 2023?

Answer:

I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Name of medicine	Number patients treated
9.1 Olaparib in total	25
9.2 Olaparib monotherapy	25
9.3 Olaparib + bevacizumab in combination	Nil
9.4 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin	≤5

Question:

10. How many patients were treated for **endometrial cancer** with the following medicines as monotherapy or in combination, in the 3 months between the start of October 2023 and end of December 2023?

Answer:

Name of medicine	Number patients treated
10.1 Dostarlimab monotherapy	≤5
10.2 Dostarlimab + platinum-based chemotherapy, or dostarlimab + carboplatin and paclitaxel	Nil
10.3 Pembrolizumab (Keytruda) in total	≤5
10.4 Lenvatinib (Lenvima) in total	≤5
10.5 Pembrolizumab monotherapy	Nil
10.6 Pembrolizumab + Lenvatinib (Lenvima) in combination	≤5

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the reviewer at the address at the top of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI>

Yours sincerely

ALISON MACDONALD
Executive Director of Nursing Midwifery and AHPs
 Cc: Chief Executive